GFH276 / GenFleet Therap - LARVOL DELTA

GenFleet Therapeutics…is pleased to announce that the Company will exhibit preclinical research data of three compounds - GFH276 (non-degrading molecular glue), GFS784 (novel antibody-drug conjugate linking functional antibody with synergistic targeted payload) and GFH603 (molecular glue-like covalent allosteric activator) - at the poster presentation of the 2026 AACR Annual Meeting (HKEXnews)

Preclinical • Oncology

Preclinical evaluation of GFH276 monotherapy and combination therapy for RAS-mutant tumors (AACR 2026) - P1/2 | "Here we present a further pre-clinical assessment of GFH276 monotherapy and its rational combination with distinct therapeutic agents. BULB/c nude mice bearing CDX tumors harboring different KRAS mutations were used to determine the anti-tumor efficacy of GFH276 monotherapy or its combination with Cetuximab. GFH276 monotherapy was effective in mouse models harboring tumors originating from most common RAS-mutant cancers. GFH276 also showed synergistic effects with anti-EGFR mAb and immunotherapy. These results depict the promising therapeutic potential of GFH276 in broad indications via different application strategies."

Combination therapy • IO biomarker • Monotherapy • Preclinical • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Uterine Cancer • KRAS

A Single-Arm, Open-Label, Multicenter Phase I/II Clinical Study of GFH276 in Patients With RAS-Mutant Advanced Solid Tumors (clinicaltrials.gov) - P1/2 | N=450 | Not yet recruiting | Sponsor: Genfleet Therapeutics (Shanghai) Inc.

New P1/2 trial • Colorectal Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

FIRST PATIENT DOSED WITH GFH276, A MOLECULAR GLUE PAN RAS (ON) INHIBITOR, IN A PHASE I/II STUDY TREATING RAS-MUTANT CANCER PATIENTS (HKEXnews) - "The phase Ia trial of GFH276 will be conducted at approximately 10 investigational sites including the Sun Yat-sen University Cancer Center in southeastern China and Fudan University Shanghai Cancer Center."

Trial status • Solid Tumor

GFH276: A molecular glue panRAS(on) inhibitor with broad spectrum anti-tumor activities (AACR 2025) - "Compared to SIIP-based KRAS G12C inhibitors Sotorasib, Adagrasib and Divarasib, GFH276 was not susceptible to upstream RTK-reactivation by EGF stimulation and remained effective against cell lines carrying second KRAS mutations or RTK alterations or with induced resistance to Sotorasib. GFH276 demonstrated strong therapeutic activities in tumors with activating RAS and RTK alterations. Encouraged by these promising results, we are advancing GFH276 into the Phase 1 clinical trial by conducting IND-enabling studies and the IND submission is planned in Q2 2025."

Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • BRAF • EGFR • FGFR2 • HRAS • KRAS • NRAS